About this trial
The goal of this clinical trial is to learn if it is feaseble to conduct a superiority trial comparing two methods for endotracheal intubation in critically ill patients. It will also learn about validity of outcomes regarding endotracheal intubation. The main questions it aims to answer are:
* Does performing intubation via Delayed Sequence Induction lower the incidence of severe hemodynamic complications compared to Rapid Sequence Induction? * How are hemodynamic complications in the severely ill to be measured in order to minimize bias?
Participants will:
* receive emergency endotracheal intubation via Delayed or Rapid Sequence induction * receive a phone call 90 days after endotracheal intubation * outcome parameters outside of follow up phone calls will be routinely collected during the regular ICU-stay, there won't be any additional testing
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult patients 18 years or older in need of emergency endotracheal intubation in the following 60 minutes.
The planned operateur routinely performs endotracheal intubation in critically ill patients.
Disqualifiers
Endotracheal Intubation performed during cardiopulmonary resuscitation or during "unstable ROSC", defined as Norepinephrine or Epinephrine dose > 0,5 µg/kgKG/min after return of spontaneous circulation.
Participation in the study is not warranted because of increased risk for the patient or otherwise not justifiable (e.g. active oral bleeding).
Known allergy against Ketamine, Esketamine, Midazolam or Rocuronium.
Known contraindication against Ketamine, Esketamine Midazolam or Rocuronium.
Trial design
Parallel
Treatments tested in this trial
Delayed Sequence Induction
Procedure/SurgeryDelayed Sequence Induction - fractional dosing of Ketamin and Midazolam until a dissociative status is achieved. Dosing should follow the clinical effect. - start of preoxygenation with Bag-Valve-Mask Device or NIV when dissociative status is achieved for at least 3 minutes. - after completion of preoxygenation: neuromuscular blockade with Rocuronium - after application of Rocuronium: Intubation via standard of care. - should apnoea occur during preoxygenation, the continuation of ventilation via Bag-Valve-Mask or NIV is recommended, but not mandatory.
Modified Rapid Sequence Induction
Procedure/SurgeryModified Rapid Sequence Induction - Preoxygenation FiO2 100% with Bag-Valve-Mask-Device or NIV for at least 3 Minutes. - After completion of Preoxygeniation: application of Midazolam, Ketamin and Rocuronium. - The dosing of medication is determined in advance by the operating physician. - Ventilation via Bag-Valve-Mask-device or NIV after application of rocuronium is allowed. - After application of medication: Intubation via standard of care.
Treatment groups
Trial outcomes
Primary outcomes
Cardiovascular Collapse
Composite Outcome: Hemodynamic Instability up to 60 minutes after start of the procedure, defined as: * any measured RRsyst \< 65 mmHg or RRsyst \< 90 mmHg for at least 30 minutes and/or * new need for Norepinephrine or increased dosage of Norepinephrine or need of a volume bolus \> 15 ml/kgKG, to sustain a MAP \> 65 mmHg/RR syst \> 90 mmHg. and/or Cardiopulmonary Resuscitation up to 60 minutes after start of the procedure.
Secondary outcomes
Hemodynamic Instability
Hemodynamic Instability up to 60 minutes after start of the procedure, defined as: - any measured RRsyst \< 65 mmHg or RRsyst \< 90 mmHg for at least 30 minutes and/or - new need for Norepinephrine or increased dosage of Norepinephrine or need of a volume bolus \> 15 ml/kgKG, to sustain a MAP \> 65 mmHg/RR syst \> 90 mmHg.
Cardiopulmonary Resuscitation
Cardiopulmonary Resuscitation, defined as any start of chest compressions.
spO2 after completion of preoxygenation
spO2 \[%\] after completion of preoxygenation
Lowest spO2 during procedure
Lowest spO2 during procedure
Sponsors and contacts
Click on the lead sponsor to view all of their trials.